{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T08:09:47Z","timestamp":1793261387008,"version":"4.5.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2004,5,1]],"date-time":"2004-05-01T00:00:00Z","timestamp":1083369600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,7]],"date-time":"2015-12-07T00:00:00Z","timestamp":1449446400000},"content-version":"vor","delay-in-days":4237,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2004,5]]},"DOI":"10.1111\/j.1523-1755.2004.00588.x","type":"journal-article","created":{"date-parts":[[2004,4,13]],"date-time":"2004-04-13T14:15:02Z","timestamp":1081865702000},"page":"1842-1849","source":"Crossref","is-referenced-by-count":223,"title":["Mycophenolate mofetil in IgA nephropathy: Results of a 3-year prospective placebo-controlled randomized study"],"prefix":"10.1016","volume":"65","author":[{"given":"Bart D.","family":"Maes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond","family":"Oyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Claes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter","family":"Evenepoel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Kuypers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Vanwalleghem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boudewijn Van","family":"Damme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves F. Ch","family":"Vanrenterghem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1111\/j.1523-1755.2004.00588.x_bb0010","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1056\/NEJMra020109","article-title":"IgA nephropathy","volume":"347","author":"Donadio","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1523-1755.2004.00588.x_bb0015","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/ki.1995.50","article-title":"IgA nephropathy","volume":"47","author":"Galla","year":"1995","journal-title":"Kidney Int"},{"key":"10.1111\/j.1523-1755.2004.00588.x_bb0020","doi-asserted-by":"crossref","first-page":"F1167","DOI":"10.1152\/ajprenal.00209.2002","article-title":"Experimental and clinical rationale for use of MMF in nontransplant progressive nephropathies","volume":"283","author":"Zatz","year":"2002","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1111\/j.1523-1755.2004.00588.x_bb0025","first-page":"709","article-title":"The commonest glomerulonephritis in the world: IgA nephropathy","volume":"645","author":"D'Amico","year":"1987","journal-title":"Q J Med"},{"key":"10.1111\/j.1523-1755.2004.00588.x_bb0030","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0002-9343(88)90019-8","article-title":"IgA nephropathy, the most common glomerulonephritis worldwide: A neglected disease in the United States?","volume":"84","author":"Julian","year":"1988","journal-title":"Am J Med"},{"key":"10.1111\/j.1523-1755.2004.00588.x_bb0035","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S0002-9343(01)00684-2","article-title":"Immunoglobulin A nephropathy with mild renal lesions: A call in the forest for physicians and nephrologists","volume":"110","author":"Schena","year":"2001","journal-title":"Am J Med"},{"key":"10.1111\/j.1523-1755.2004.00588.x_bb0040","first-page":"55","article-title":"IgA-IgG nephropathy: Predictive indices of progressive disease","volume":"16","author":"Hood","year":"1981","journal-title":"Clin Nephrol"},{"key":"10.1111\/j.1523-1755.2004.00588.x_bb0045","first-page":"65","article-title":"Clinical and histopathologic associations with impaired renal function in IgA nephropathy","volume":"41","author":"Donadio","year":"1994","journal-title":"Clin Nephrol"},{"key":"10.1111\/j.1523-1755.2004.00588.x_bb0050","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1681\/ASN.V82199","article-title":"Predicting renal outcome in IgA nephropathy","volume":"8","author":"Radford","year":"1997","journal-title":"J Am Soc Nephrol"},{"key":"10.1111\/j.1523-1755.2004.00588.x_bb0055","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/S0140-6736(05)60198-5","article-title":"Mycophenolate mofetil for systemic vasculitis and IgA nephropathy","volume":"349","author":"Nowack","year":"1997","journal-title":"Lancet"},{"key":"10.1111\/j.1523-1755.2004.00588.x_bb0060","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1046\/j.1523-1755.2002.00214.x","article-title":"Mycophenolate mofetil treatment for primary glomerular diseases","volume":"61","author":"Choi","year":"2002","journal-title":"Kidney Int"},{"key":"10.1111\/j.1523-1755.2004.00588.x_bb0065","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0162-3109(00)00188-0","article-title":"Mycophenolate mofetil and its mechanisms of action","volume":"47","author":"Allison","year":"2000","journal-title":"Immunopharmacology"},{"key":"10.1111\/j.1523-1755.2004.00588.x_bb0070","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1749-6632.1993.tb35881.x","article-title":"Immunosuppressive activity of mycophenolate mofetil","volume":"685","author":"Eugui","year":"1993","journal-title":"Ann NY Acad Sci"},{"key":"10.1111\/j.1523-1755.2004.00588.x_bb0075","first-page":"3205","article-title":"Preferential suppression of lymphocyte proliferation by mycophenolic acid and predicted long-term effects of mycophenolate mofetil in transplantation","volume":"26","author":"Allison","year":"1994","journal-title":"Transpl Proc"},{"key":"10.1111\/j.1523-1755.2004.00588.x_bb0080","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1399-0012.1996.tb00651.x","article-title":"Purine metabolism and immunosuppressive effects of mycophenolate mofetil (MMF)","volume":"10","author":"Allison","year":"1996","journal-title":"Clin Transplant"},{"key":"10.1111\/j.1523-1755.2004.00588.x_bb0085","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/00007890-199508000-00003","article-title":"Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients","volume":"60","author":"Sollinger Hw, for the U.S. Renal Transplant Mycophenolate Mofetil Study Group","year":"1995","journal-title":"Transplantation"},{"key":"10.1111\/j.1523-1755.2004.00588.x_bb0090","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/S0140-6736(95)92534-1","article-title":"Placebo-controlled study of mycophenolate mofetil combined with cyclosporine and corticosteroids for prevention of acute rejection","volume":"345","author":"European Mycophenolate Mofetil Cooperative Study Group","year":"1995","journal-title":"Lancet"},{"key":"10.1111\/j.1523-1755.2004.00588.x_bb0095","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1097\/00007890-199604150-00008","article-title":"A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation","volume":"61","author":"Tricontinental Mycophenolate Mofetil Study Group","year":"1996","journal-title":"Transplantation"},{"key":"10.1111\/j.1523-1755.2004.00588.x_bb0100","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1053\/ajkd.1998.v31.pm9469489","article-title":"Successful mycophenolate mofetil treatment of glomerular disease","volume":"31","author":"Briggs","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"10.1111\/j.1523-1755.2004.00588.x_bb0105","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1053\/ajkd.2000.8968","article-title":"Use of mycophenolate mofetil in resistant membranous nephropathy","volume":"36","author":"Miller","year":"2000","journal-title":"Am J Kidney Dis"},{"key":"10.1111\/j.1523-1755.2004.00588.x_bb0110","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1681\/ASN.V1091965","article-title":"Mycophenolate mofetil for maintenance therapy of Wegener's granulomatosis and microscopic polyangiitis: A pilot study in 11 patients with renal involvement","volume":"10","author":"Nowack","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"10.1111\/j.1523-1755.2004.00588.x_bb0115","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1056\/NEJM200010193431604","article-title":"Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis","volume":"343","author":"Chan","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1523-1755.2004.00588.x_bb0120","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1046\/j.1523-1755.1998.00138.x","article-title":"Mycophenolate mofetil attenuates renal injury in the rat remnant kidney","volume":"54","author":"Fujihara","year":"1998","journal-title":"Kidney Int"},{"key":"10.1111\/j.1523-1755.2004.00588.x_bb0125","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1046\/j.1523-1755.1999.055003945.x","article-title":"Mycophenolate mofetil prevents the progressive renal failure induced by 5\/6 renal ablation in rats","volume":"55","author":"Romero","year":"1999","journal-title":"Kidney Int"},{"key":"10.1111\/j.1523-1755.2004.00588.x_bb0130","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1046\/j.1523-1755.2003.00811.x","article-title":"Mycophenolate mofetil prevents arteriolopathy and renal injury in subtotal ablation despite persistent hypertension","volume":"63","author":"Tapia","year":"2003","journal-title":"Kidney Int"},{"key":"10.1111\/j.1523-1755.2004.00588.x_bb0135","series-title":"Classification and Atlas of Glomerular Disease","article-title":"Renal disease,","author":"Churg","year":"1982"},{"key":"10.1111\/j.1523-1755.2004.00588.x_bb0140","series-title":"Release 6.03 Edition 1","author":"SAS\/STAT User's Guide","year":"1988"},{"key":"10.1111\/j.1523-1755.2004.00588.x_bb0145","series-title":"Springer Series in Statistics","first-page":"93","article-title":"Linear mixed models for longitudinal data,","author":"Verbeke","year":"2000"},{"key":"10.1111\/j.1523-1755.2004.00588.x_bb0150","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1681\/ASN.V112283","article-title":"Combined mycophenolate mofetil and losartan therapy arrests established injury in the remnant kidney","volume":"11","author":"Fujihara","year":"2000","journal-title":"J Am Soc Nephrol"},{"key":"10.1111\/j.1523-1755.2004.00588.x_bb0155","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1681\/ASN.V9122272","article-title":"Mycophenolate mofetil prevents the induction of active Heymann nephritis: Association with Th2 cytokine inhibition","volume":"9","author":"Penny","year":"2000","journal-title":"J Am Soc Nephrol"},{"key":"10.1111\/j.1523-1755.2004.00588.x_bb0160","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1681\/ASN.V1071542","article-title":"Combining an antiproteinuric approach with mycophenolate mofetil fully suppresses progressive nephropathy of experimental animals","volume":"10","author":"Remuzzi","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"10.1111\/j.1523-1755.2004.00588.x_bb0165","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1056\/NEJM199411033311804","article-title":"A controlled trial of fish oil in IgA nephropathy","volume":"331","author":"Donadio","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1523-1755.2004.00588.x_bb0170","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1681\/ASN.V124791","article-title":"A randomised trial of high-dose compared with low-dose omega-3 fatty acids in severe IgA nephropathy","volume":"12","author":"Donadio","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"10.1111\/j.1523-1755.2004.00588.x_bb0175","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/00007890-199907270-00018","article-title":"A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation","volume":"68","author":"van Gelder","year":"1999","journal-title":"Transplantation"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S008525381549917X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S008525381549917X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,15]],"date-time":"2024-12-15T20:55:32Z","timestamp":1734296132000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S008525381549917X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,5]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2004,5]]}},"alternative-id":["S008525381549917X"],"URL":"https:\/\/doi.org\/10.1111\/j.1523-1755.2004.00588.x","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2004,5]]}}}